Drug profile · INN
coronavirus (sars-cov-2) rna vaccine
DAICHIRONA PARTIAL CHANGE APPROVAL
coronavirus (sars-cov-2) rna vaccine (DAICHIRONA PARTIAL CHANGE APPROVAL) is an FDA-listed pharmaceutical active ingredient.
PMDA: approved
Patents linked 1
Pipeline programs 5
News articles 0
Drug details — coronavirus (sars-cov-2) rna vaccine
- Class
- —
- Route
- —
- Patents
- 1
- Programs
- 5
- Data quality
- 0.78
Quick answer
coronavirus (sars-cov-2) rna vaccine (DAICHIRONA PARTIAL CHANGE APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN coronavirus (sars-cov-2) rna vaccine
Brand DAICHIRONA PARTIAL CHANGE APPROVAL
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Pipeline programs
Related patents
Frequently asked questions
What is coronavirus (sars-cov-2) rna vaccine?
coronavirus (sars-cov-2) rna vaccine (DAICHIRONA PARTIAL CHANGE APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for coronavirus (sars-cov-2) rna vaccine?
DAICHIRONA PARTIAL CHANGE APPROVAL is a marketed brand name for coronavirus (sars-cov-2) rna vaccine. Check FDA Drugs@FDA for the current US label holder and prescribing information.